Treatment of osteopenia
- First Online:
- Cite this article as:
- Eriksen, E.F. Rev Endocr Metab Disord (2012) 13: 209. doi:10.1007/s11154-011-9187-z
- 2.2k Downloads
The majority of osteoporotic fractures happen in individuals with BMD t-scores in the osteopenic range (−2, 5< t-score <−1). However, widespread use of anti-osteoporotic medication in this group based on t-score alone is not advisable because: 1) the number needed to treat is much higher (NNT > 100) than in patients with fractured and t-score below −2,5 (NNT 10–20); 2)while specific osteoporosis treatments have demonstrated significant reductions of the fracture risk in patients with t-score <−2, 5, the efficacy in patients in the osteopenic range is less well established. Therefore, an osteopenic t-score does not in itself constitute a treatment imperative. Generally, osteopenia has to be associated with either low energy fracture(s) or very high risk for future fracture as assessed with risk calculators like FRAX to warrant specific osteoporosis therapy. Vertebral fractures are now conveniently assessed using lateral x-rays from DXA machines. In the vast majority of cases antiresorptive treatments (mainly hormone replacement therapy and SERMS in younger and bisphosphonates or Denosumab in older women) are the treatments of choice in this group of patients,—only rarely is anabolic therapy indicated.
KeywordsOsteopenia Osteoporosis DXA FRAX Hormone replacement therapy SERM Bisphosphonates Parathyroid hormone
Osteoporosis leading to low energy fracture is often compared to hypertension leading to stroke. We have implemented widespread screening for high blood pressure and the intervention threshold is low. Thus, from a general health point of view, it would be beneficial to detect individuals at risk for low energy fracture and intervene before the catastrophic event,—with all its potential complications, happened. However, most clinicians are still hesitant implying aggressive pharmacologic treatment strategies in osteopenic patients. Several reasons for this apprehension have been cited:
First, perceptions around disease severity are different when comparing hypertension and osteoporosis. in the mind of most clinicians. Osteoporotic fracture is considered a far less severe event than stroke, although the increase in mortality and morbidity after spine or hip fractures is significant [2, 3].
Second, pharmaco-economic considerations also play a role. A lot of these discussions have centered around estimates of numbers needed to treat (NNT). While the most effective antiresorptive treatment today have NNT values for prevention of one fracture around 13–15 for spine fractures similar numbers in osteopenia patients are 8–10 fold higher [4, 5]. As shown in the analysis of Quandt et al.  the presence of a prevalent fracture yields a NNT for subsequent fracture over the next 5 years of 26, compared to 125 in patients without fractures at entry into the study. The fact that most patients with osteopenia are younger than the typical osteoporotic women is also important. Riancho (1999) reported that NNT for hip fractures ranged from 7 (for women aged 80 with a bone mineral density [BMD] with Z-scores <−2) to 333 (for women aged 50 with Z-scores between 0 and −1). Based on these assumptions they calculated that therapy of 100 women aged 80 years with a Z value <−2 for 3 years would prevent 14 hip fractures, 33 vertebral fractures and 8 wrist fractures. Therapy of 100 women aged 50–55 years with a Z value ranging from 0 to −1 would only prevent 1 hip fracture, 2 vertebral fractures and 2 wrist fractures . Along the same lines Lamy and Krieg reported the results of economic analyses, which took into account the health care resources needed to get these benefits. They found that at 50 years, only calcium and vitamin D was cost-effective, whereas at 70 years, bisphosphonates and raloxifene were also cost-effective .
Third, a few studies, in particular on bisphosphonates, have hinted that clinical fractures were only significantly reduced in patients with t-scores <−2,5 . In the same study, however, morphometric fractures were reduced even in patients with a t-score >2,5.
Most guidelines for osteopenic patients therefore primarily emphasize lifestyle changes like smoking cessation, nutritional improvements, calcium and vitamin D supplementation, exercise regimens etc. as primary interventions . However, as seen from the NORA data, a significant number of high-risk osteopenic patients will still need pharmacologic intervention in order to reduce their fracture risk significantly. Identification of these individuals, however, demand effective case finding strategies. This review will summarize the current status of such strategies and the treatment options available and end op proposing a treatment algorithm based on this information.
1.1 Case finding strategies
While bone density remains one of the most valid and reliable measures of fracture risk, a better delineation of risk factors has led to renewed interest in absolute risk (AR) models such as FRAX. New imaging approaches, including lateral VFA, have been added to the diagnostic armamentarium, and facilitate identification of fractures earlier and with less radiation exposure to the patient. This is important because of the severe consequences of prevalent fractures in osteopenia as well as osteoporosis, not only of the hip but also of the much more common spine fractures.
1.1.1 Identification of osteopenic patients at increased risk of fracture
BMD is related to bone strength and low BMD is a major risk factor for fractures. However, most patients presenting with a fracture do not have BMD based osteoporosis, defined according to the World Health Organization (WHO) definition as a T score of −2.5 or below. The most poignant example is hip fracture, where only half the patients exhibit t-scores below −2.5 . In addition, and independent of bone-related risks, extraskeletal risk factors such as falls contribute to fracture risk and are present in the majority of patients older than 50 years presenting with a clinical fracture, and falls are the dominant event leading to forearm and hip fracture .
1.1.2 Identification of patients with prevalent fractures
The primary risk factor for subsequent fracture is a prevalent low energy fracture, irrespective of whether it is clinically apparent or not. Thus, most guidelines for treatment consider the presence of a low energy fracture in an osteopenic patient a clear indication for specific osteoporosis therapy [9, 12, 13]. A history of nonvertebral fracture is associated with a doubling of the risk of a subsequent fracture, and the subsequent fracture risk is even quadrupled after a vertebral fracture. The re-fracture risk is, however, not constant over time. It is highest (2–3X) in the years immediately after a first fracture, followed by a gradual waning later on . Forty to 50% of all subsequent fractures occur within 3 to 5 years after a first fracture, and the presence of such fractures demands rapid intervention with specific osteoporosis drugs to reduce the risk of a subsequent fracture. Prevalent hip, spine and several other nonvertebral fractures are all associated with increased morbidity and mortality , which is higher immediately after fracture than later on. Hip, vertebral, and nonhip, nonvertebral fractures were each associated with approximately one third of deaths. The major causes of death were related to cardiovascular and respiratory comorbidities .
Unfortunately subsequent follow up of fracture patients after orthopedic fracture repair to identify patients in need of specific osteoporosis treatment is still very limited. Most studies show that only 10–15% of fracture patients treated at orthopedic departments are offered a DXA evaluation, and even less patients ar offered supplementation with vitamin D and Ca or specific osteoporosis treatment. Fortunately a lot of centres are recognizing this dilemma and have established initiatives for post-fracture care (e.g. fracture liaison service . Such interventions have the potential to reduce subsequent fractures, morbidity, mortality and readmissions to hospital.
While hip and other nonvertebral fractures are clinically obvious, the detection of vertebral fractures constitutes a significant problem. Morphometric vertebral fractures are the most frequent fractures in women and men older than 50 years  and their presence is a strong predictor of future vertebral, nonvertebral, and hip fracture risk [18, 19]. Clinical vertebral fractures are characterized by back pain lasting for 2–3 months, depending on fracture severity, but they represent only a small subgroup of all vertebral fractures. In recent large scale trials they constitute less than 10% of all morphometric fractures [20, 21]. Most morphometric vertebral fractures therefore remain undiagnosed, which results in many patients developing severe osteoporosis with multiple fractures and chronic pain, before effective treatment is instituted. Only when clinical suspicion, e.g. significant height loss, increasing kyphosis, protruding abdomen, rib-iliac crest distance of less than 2 cm, and acute or chronic back pain, is raised, a spine x-ray is performed. But even when lateral x-rays of the spine are available, vertebral fractures are often missed [22, 23].
Indications for vertebral fracture assessment using x-ray absorptiometry after 
1. Postmenopausal women with low bone mass (osteopenia) by BMD criteria plus one of the following:
- Age of greater than or equal to 70 years.
- Historical height loss of greater than 4 cm.
- Prospective height loss of greater than 2 cm.
- Self-reported prior vertebral fracture (not previously documented).
- Two or more of the following:
Age of 60 to 69 years.
Self-reported prior nonvertebral fracture.
Historical height loss of 2 to 4 cm.
Chronic systemic diseases associated with increased risk of vertebral fractures (for example, moderate to severe chronic obstructive pulmonary disease (COPD), seropositive rheumatoid arthritis, and Crohn disease).
2. Men with low bone mass (osteopenia) by BMD criteria plus one of the following:
- Age of 80 years or older.
- Historical height loss of greater than 6 cm.
- Prospective height loss of greater than 3 cm.
- Self-reported vertebral fracture (not previously documented).
- Two or more of the following:
Age of 70 to 79 years.
Self-reported prior nonvertebral fracture.
Historical height loss of 3 to 6 cm.
On pharmacological androgen deprivation therapy or following orchiectomy.
Chronic systemic diseases associated with increased risk of vertebral fractures (for example, moderate to severe COPD, seropositive rheumatoid arthritis, and Crohn disease).
3. Women or men on chronic glucocorticoid therapy (equivalent to 5 mg or more of prednisone daily for 3 months or longer).
4. Postmenopausal women or men with osteoporosis by bone density criteria (total hip, femoral neck, or lumbar spine T score of not more than −2.5) if documentation of one or more vertebral fractures will alter clinical management.
If pathology outside this region of interest (ROI) is suspected, other imaging techniques will have to used. The experience in most centres employing this methodology is, however, that such referrals are needed in less than 10% of cases. According to the International Society of Clinical Densitometry (ISCD), additional x-ray imaging is needed in cases of two or more mild (grade 1) deformities without any moderate or severe (grade 2 or 3) deformities, when lesions in vertebrae cannot be ascribed to benign causes, or when vertebral deformities are found in a patient with a known history of a relevant malignancy . The methodology also permits assessment of spondylosis and even arteriosclerosis of the abdominal aorta can be evaluated.
The prevalence of previously unknown morphometric vertebral fractures has been studied in various at-risk populations. In a recent study of women and men presenting with a nonvertebral fracture, one out of four had a prevalent morphometric vertebral fracture on VFA that was not recognized previously . In another study, the prevalence of morphometric vertebral fractures was 21% in postmenopausal women with osteopenia .
In patients with BMD-diagnosed osteoporosis, a baseline VFA is not necessary for treatment decisions but is helpful in detecting lack of treatment efficacy during follow-up. Fractures occurring in L1-L4 will increase apparent BMD, and may be difficult to see on the standard AP image provided by a routine scan.
1.1.3 Identification of high risk individuals without fracture history - the fracture risk assessment tool (FRAX)
Clinical risk factors and bone densitometry results that are included in the Fracture Risk Assessment Tool algorithm
Body mass index
History of fracture after the age of 45 to 50 years
Parent with hip fracture
Alcohol intake of greater than 2 units per day
Other causes of secondary osteoporosis:
- Untreated hypogonadism in men and women, anorexia nervosa, chemotherapy for breast and prostate cancer and hypopituitarism
- Inflammatory bowel disease and prolonged immobility (for example, spinal cord injury, Parkinson disease, stroke, muscular dystrophy, and ankylosing spondylitis)
- Organ transplantation
- Type I diabetes and thyroid disorders (for example, untreated hyperthyroidism and overtreated hypothyroidism)
Femoral neck BMD.
The National Osteoporosis Foundation (NOF) in the US and the National Osteoporosis Society (NOS) in the UK have integrated FRAX and BMD for case finding of individuals at high risk for fracture and for treatment decisions in their new guidelines. Treatment thresholds were put at 10-year fracture risk estimates from the FRAX algorithm, at which fracture prevention became cost-effective. Generally FRAX based ten year risks of 20% or higher for all osteoporotic fractures and 3% or higher for hip fracture are considered reasonable intervention thresholds [12, 13].
FRAX identifies patients at increased risk of osteoporotic fracture based on some of the dominant risk factors, but cannot be used in isolation. Several known determinant of fracture risk are, however, not included in FRAX. The algorithm does not take into account well known “dose effects” like glucocorticoid dose. Incorporation of BMD results is limited to results of BMD in the femoral neck. However, total hip BMD is a more precise measure and can be used interchangeably with femoral neck BMD in women, but not in men. Vitamin D deficiency, a well established risk factor for falls and hip fracture is not included. The same holds for bone markers, which have been shown to independently affect fracture risk. FRAX may also underestimate fracture risk in individuals with increased propensity for falls. More than 80% of women and men presenting with a clinical fracture to the emergency unit have one or more fall-related risks and exhibit a fourfold increased risk of falls in the year leading up to admission. In another study on 5- and 10-year absolute risks for fractures in patients using glucocorticoids, a history of falls had a greater impact on fracture risk than any other evaluated risk . Finally it is important to remember that FRAX is only applicable in untreated patients. It cannot be used as a helper in decision making in patients, who already receive specific osteoporosis treatment. A recent study from Switzerland used FRAX to identify patient profiles with increased probability of fracture beyond currently accepted reimbursement thresholds for BMD and osteoporosis. The study found that in particular age, BMI and parental history of fracture increased the risk fo fracture substantially .
In patients with BMD-based osteoporosis or presenting with a clinical fracture or both, diagnostic evaluation is necessary to exclude secondary osteoporosis. Such evaluations should include hematologic parameters (Hb, WBC), serum 25-(OH)D3, calcium, creatinine, thyroid-stimulating hormone, parathyroid hormone (PTH), serum/urine electrophoresis and testosterone (in me). According to the clinical picture and suspicion, other serum measurements such as plasma cortisol, tests for celiac disease and selected other evaluations looking for secondary causes are indicated . It is generally considered that secondary causes of osteoporosis are more common in men than women. Among secondary causes, hypogonadism resulting from the treatment of breast cancer with aromatase inhibitors use of androgen deprivation therapies in have become an emerging clinical problem .
There is general consensus on the need for specific osteoporosis treatment in patients with spine or hip fractures and low BMD. For other nonvertebral fractures different societies advocate different strategies. The NOS recommends drug treatment in all postmenopausal women with a history of any fragility fracture , while the NOF advocates performing a dual-energy x-ray absorptiometry (DXA) on patients after nonvertebral fractures to decide, whether specific osteoporotic therapy is indicated. Drug treatment should then be considered in patients having osteoporosis and in patients with osteopenia when FRAX indicates a 10-year fracture probability of at least 3% for hip or at least 20% for major fractures .
1.2 Treatment options
1.2.1 Lifestyle changes
General changes in life style like smoking cessation, regular exercise and optimization of nutirition should be implemented in all osteopenic patients. Patient compliance with these measures is, however, poor, and very few prospective data on the anti-fracture efficacy of such measures exist.. Smoking has emerged as a significant risk factor for fracture in many epidemiological studies [30, 31, 32], albeit the influence of dose and duration is less well defined. The same holds for exercise [33, 34], but exercise can slow down bone loss after menopause and is important for muscular strength and coordination in the elderly . The impact of poor nutrition on skeletal health is apparent in its most extreme form in anorexia nervosa, where significant improvement of skeletal mass is important without a reversal of caloric intake in these young women [35, 36].
In recent years, vitamin D deficiency has emerged as a very important risk factor for osteoporotic fracture, especially at the hip. High turnover bone loss due to secondary hyperparathyroidism due to vitamin D deficiency is considered a major pathogenetic factor in senile osteoporosis . Vitamin D deficiency is endemic worldwide  and patients with hip fracture generally have the lowest vitamin D levels among all patient groups studied [39, 40]. Vitamin D deficiency does not only cause weaker bones due to osteomalacia, but also severe myopathy with loss of muscle strength, selective loss of the rapid type-2 fibres, dyscoordination and consequently increased propensity for falls . It is therefore not surprising that meta-analyses indicate that correction of vitamin D deficiency results in a decreased fall and fracture risk [42, 43], but the effects depend on the dose of vitamin D and the target population . It is still a matter of debate which doses of vitamin D3 or D2 supplementation are necessary/optimal, taking into account baseline vitamin D status and the desired serum levels to be achieved by supplementation [31, 32, 33]. Daily intake of 400 IU/day is not sufficient, while 800 IU/day reduce falls and fractures significantly [42, 43]. In a recent controlled clinical trial Bischoff-Ferrari et al. demonstrated that in a population of post hip fracture patients maybe even higher doses are warranted. In this study a dose of 2,000 IU/day of D3 was superior to 800 IU/day in a cohort of 176 patients all undergoing moderate physiotherapy. Over a 1 year period the dose of 200 IU resulted in 25% less falls, 39% less readmissions to hospital and a staggering 90% reduction in all cause infections, when compared to 800 IU per day .
Several reviews have emphasized the need of addition of calcium to vitamin D for fracture prevention and a dose of 1,000 to 1,200 mg/day was advocated . Whether the calcium dose can get too high is still a matter of debate, but studies from one center published in 2008 reported that supplements of 1,000 mg calcium/day on top of a baseline intake of 800 mg/day increased the risk of vascular events including myocardial infarction in healthy postmenopausal women men [47, 48]. In this context, it is reassuring that, when intake of vitamin D3 is sufficient, the need for calcium intake is considered to be lower .
1.2.2 Prevention of falls and protection against fall trauma
Over 90% of hip fractures and all Colles fractures are caused by falls, mostly in house. Vitamin D supplements improve muscle function and decrease the risk of falls, as discussed above. The role of physical exercise is still debated, but exercise interventions together with other measures such as removing loose carpets, reduce use of sleep medicine and other tranquilizers, correct visual impairment etc. reduce the risk and rate of falls in older people living in the community , but no data that fall prevention decreases the risk of fracture are yet available. The role of hip protectors remains controversial. They seem to work in nursing homes [51, 52], but less in community dwelling elderly, mainly due to discomfort and practicality [53, 54].
The last 2 decades have seen the emergence of an ever growing list of effective and safe pharmacological agents for the treatment of osteoporosis. These therapies for the prevention and treatment of osteoporosis affect bone remodeling by either inhibiting bone resorption (antiresorptive or anti-activation drugs) or enhancing bone formation (anabolic regimens). Antiresorptive drugs do not lead to net accrual of bone in the skeleton, despite the fact that BMD is increased. They mainly act by reducing bone turnover (therefore the term anti-activation), thus reducing the impact of the negative remodeling balance present in osteoporotics  and limiting further deterioration of cancellous- and cortical bone structure . These drugs also reduce the remodeling space and increase the degree by which bone matrix is mineralized, which is behind the increase in BMD and add to the antifracture efficacy of these agents. On average, these drugs increase DXA BMD by 2–10%, and this increase is mainly caused by reduced porosity of cortical and cancellous bone combined with the increased incorporation of bone mineral into bone matrix during low turnover. Antiresorptives belonging to the bisphosphonate group are the most widely used agents. These agents have shown significant efficacy in randomized trials reducing event rates by up to 70% for spine fractures, 40–50% for hip fractures and 20–25% for nonvertebral fractures overall. Clinical painful spine fractures show reductions of up to 85–90% [21, 57, 58, 59]. In hip fracture patients, treatment with iv.bisphosphonatea furthermore has demonstrated a significant 28% reduction of all cause mortality.
Anabolic drugs, of which only recombinant PTH are currently available, on the other hand add net bone mass to the skeleton and actually improve bone structure and increase bone size from the osteoporotic state [60, 61].
Despite the advances in pharmacotherapy the majority of patients with osteopenia and osteoporosis are not treated , and for patients who initiate therapy, adherence to therapy is commonly below 50% at 1 to 2 years .
1.3 Antiresorptive (anti-activation) drugs
Estrogen receptors have been demonstrated on both osteoblasts and osteoclasts [62, 63]. Estrogen replacement therapy (ERT) or combined estrogen/progestin therapy (HRT) reduces bone turnover by about 50% and improves bone balance at each invidual BMU in postmenopausal women . The Women’s Health Initiative (WHI), a randomized study comprising over 16,000 postmenopausal women, demonstrated a significant 34% reduction of hip fractures after treatment with combined conjugated equine estrogen and  as well as estrogen alone in those women who had undergone hysterectomy . The study, however, also found a nearly 30% increased risk of coronary heart disease, 40% increased risk of stroke, increased risk of thromboembolic events and 26–35% increased risk of breast cancer. These results led to less enthusiasm for long-term estrogen therapy world wide. The decision to initiate ERT/HRT should be individualized and based on a balanced assessment of risk and benefits by the physician and patient. Current recommendations support restricting the use of estrogen in most women to 5 years in the perimenopausal period , with the aim mainly to reduce hot flushes and other postmenopausal symptoms, and regular mammography should be performed.
1.3.2 Selective estrogen receptor modulators
Selective estrogen receptor modulators (SERMs) are non-steroidal synthetic agents, which exert estrogen-like properties on the bone and cardiovascular systems, but estrogen antagonistic actions in the breast and, in some cases, the endometrium. The first SERM developed both for breast cancer prevention and for osteoporosis, raloxifene, is now approved in many countries for the treatment of osteoporosis. This drug was tested in the pivotal Multiple Outcomes of Raloxifene Evaluation (MORE), a multicenter study of over 7,700 postmenopausal women with at least one vertebral fracture or osteoporosis on the basis of a T score of −2.5 or below. In this study a dose of 60 mg/day reduced vertebral fracture risk by 30% in patients with prevalent fracture and 52% in patients without prevalent fracture . Similar to results obtained with another SERM mainly used in oncology, tamoxifen, the risk of invasive breast cancer was decreased by 72% during the MORE study [69, 70]. In some women hot flashes and other menopausal symptoms may recur on raloxifene. Similar to estrogen, raloxifene, increases the risk of deep venous thrombosis three-fold . The STAR trial comparing raloxifene to Tamoxifen found reported that Raloxifene was as effective as tamoxifen in reducing the risk of invasive breast cancer and carried a lower risk of thromboembolic events and cataracts, but a non-statistically significant higher risk of non-invasive breast cancer. The risk of other cancers, fractures, ischemic heart disease, and stroke was similar for both drugs .
Other SERMs, like Bazodoxifene and Lasofoxifene, are currently under development.
Bazodoxifene decreases vertebral fracture risk to a degree similar to that of raloxifene (approximately 40% over a 3-year period ) and, in a post hoc analysis, reduced the risk of non-spine fractures in a subgroup of patients with high risk for fractures based on FRAX . Lasofoxifene was studied in the Postmenopausal Evaluation And Risk reduction with Lasofoxifene (PEARL) trial. The drug caused significant reductions compared with placebo in vertebral and nonvertebral (but not hip) fracture risk as well as in estrogen receptor positive breast cancer with the 0.5 mg dose . This is the only SERM, to date showing significant reduction of nonvertebral fractures as well as significant reductions in risk of stroke, cholesterol levels and cardiovascular disease [72, 73]. In this study, however, a small rise in overall mortality was reported in the 0.25 mg dose but not with the higher 0.5 mg dose.
1.3.3 Androgen replacement therapy in males
In hypogonadal males low testosterone levels result in a high turnover state in bone leading to bone loss and increased risk of fracture. The main driver of this turnover increase is low circulating estrogen levels, just as in postmenopausal women . The low estrogen arises from insufficient aromatase conversion from testosterone, either due to low testosterone levels or insufficient aromatase activity . Testosterone replacement therapy in hypogonadism will increase circulating estradiol levels and thereby reduce bone turnover and increase BMD . In hypogonadism, usually defined as total testosterone levels below 8 nmol/l and hypogonadal symptoms , testosterone replacement will lead to increases in bone mass similar to those seen after ERT/HRT [77, 78], but randomized controlled studies with fracture end points are still lacking. Due to the fear of inducing prostate cancer clinicians have, however, been quite reluctant to institute testosterone replacement therapy. Recent data suggest, however, that prostate cancers occurring in hypogonadal males have a worse prognosis than cancers occurring in eugonadism,. Moreover, 16 population studies were unable to demonstrate any relation between testosterone levels and risk kfo prostate cancer . Nevertheless, regular controls of prostate specific antigen (PSA) and digitial rectal exploration before and after institution of therapy is still warranted.
Both injectable and intranasal administration of calcitonin results either stabilization of BMD or small increases in spine BMD (1–3%) and reductions in bone turnover as reflected in decreased levels of bone markers . A 5-year multicenter study of 1,255 postmenopausal women showed a 36% reduction in vertebral fractures in the 200 IU, but not in the two other dosage groups (100 and 400 IU). The study also had a dropout rate of around 50% . Calcitonin has been shown to improve bone structure in the forearm . Nasal calcitonin is generally well tolerated, with occasional rhinitis. Headache, flushing, nausea, and diarrhoea have been reported more commonly with subcutaneous, than with intranasal calcitonin. Due to the absence of significant reductions in hip- and nonvertebral fractures calcitonin is considered a second- or third-line agent for osteoporosis treatment in most countries.
Bisphosphonates are potent inhibitors of bone resorption and reduce the risk of osteoporotic fractures when administered orally or by intravenous infusion . They are simple molecules with a P-C-P backbone and variations in the structure of the amino side chains of these drugs determine their pharmacological activity. The most common bisphosphonates licensed and used internationally are alendronate, risedronate, ibandronate, and zoledronic acid. These drugs are used in osteoporosis, Paget disease. In higher doses (10–12 fold the doses used in osteoporosis) these drugs are used for the treatment of advanced metastatic cancer with bone involvement (e.g. multiple myeloma, breast and prostate cancer) and hypercalcemia of malignancy..
All oral bisphosphonates are poorly absorbed, with bioavailability of less than 1%. This limitation is overcome by iv administration. After absorption the drugs are primarily going to the skeleton or excreted via the kidneys. This results in absence of detectable bisphosphonate in the circulation 2–3 days after administration, while the drugs exhibit a variable but generally long skeletal retention (years to tens of years). Once adsorbed onto bone surfaces, the mechanism of action is based on two actions: 1) tight binding to hydroxyapatite crystals in bone; 2) inhibition of important metabolic pathways in osteoclasts after incorporation during resorption of bisphosphonate coated bone. The latter mechanism is either via accumulation of toxic ATP analogues for non-nitrogen containing bisphosphonates or inhibition of a key enzyme in the mevalonate pathway by nitrogen containing bisphosphonates impairing cholesterol metabolism of the osteoclast and leading to cytoskeletal alterations and premature osteoclast cell death via apoptosis .
Histomorphometric analyses of bone biopsies obtained from patients treated with bisphosphonates have revealed dose dependent reduction in bone turnover, without any adverse effects on osteoblastic function or matrix mineralization [85, 86]. A few studies have also demonstrated improved balance at the BMU-level .
Over prolonged administration, continued local inhibition of continuously deposited and recycled bisphosphonates may partially account for a lack of rapid loss of BMD gains, when these agents are discontinued , which is a unique property, compared to other osteoporosis treatments.
The main side effect of oral bisphosphonates is gastrointestinal (GI) intolerance, . Most reported GI symptoms have been non-ulcer dyspepsia, but in most clinical trials, no significant differences between those treated with bisphosphonates and those receiving placebo have been demonstrable . There have been rare reports of severe esophagitis in patients taking oral bisphosphonates .
Recently two purported adverse effects to long term bisphosphonate treatment have been reported and been subject to significant scrutiny: 1) osteonecrosis of the jaw (ONJ) 2) atypical femoral fractures. In relation to ONJ it is important to distinguish between patients receiving bisphosphonate therapy for advanced cancer with bone metastases and patients receiving the drug for the treatment of osteoporosis. In oncology only iv. Bisphosphonates are used with doses exceeding the doses used in osteoporosis by a factor of 10–12, and ONJ has been reported in an estimated 1–2% of cancer patients receiving higher doses of predominately intravenous bisphosphonates for patients with malignancies in particular . Among malignancies the vast majority of ONJ cases are seen in myeloma and breast cancer. The underlying cause of this selectivity is still unknown. Cases also have been described in patients receiving bisphosphonates for osteoporosis, but are much rarer. Several large scale studies have estimated the risk in osteoporosis to e between 1/10,000 and 1/100,000 [92, 93]. Atypical femoral fractures have also been reported in several small case series and are mostly transverse fractures of the femoral shaft in patients on long term treatment with alendronate. The fracture event is usually preceded by longstanding pain in the affected hip and most fractures happen without fall-related trauma. Bilateral fractures may occur, and on x-rays, signs of periosteal reaction and diffuse or focal cortical thickening are usually seen . Whether direct causality between bisphosphonate use and these fractures can ever be established is doubtful. In treatment naive patients atypical fractures constitute 4% of all hip fractures, and a large scale epidemiologic study from Denmark could not demonstrate any correlation to long term bisphosphonate use . Currently, the general consensus is that the benefit of significant reduction of all hip fractures after bisphosphonate treatment far outweighs the small risk of an atypical fracture, but strategies are being developed in order to identify individuals at risk.
Alendronate was the first amino-bisphosphonate approved by the US Food and Drug Administration for the treatment and prevention of osteoporosis. The registration was based on daily dosing of 10 mg/day. The Fracture Intervention Trial (FIT) enrolled 2,027 older women with at least one prior vertebral fracture and low femoral neck BMD. In this group alendronate induced significant 47% and 51% reductions in morphometric vertebral and hip fractures, respectively . In FIT subjects without prevalent vertebral fractures, alendronate 10 mg decreased radiographic vertebral fractures by 44% . A multinational study of alendronate similarly identified a 47% risk reduction for nonvertebral fractures in women with low bone mass . A long-term extension to the FIT study (FLEX) demonstrated the long term safety over a period of 10 years. With the exception of clinical vertebral fractures, fracture risk reduction at other skeletal sites was statistically indistinguishable in those receiving 5 years on followed by 5 years off of alendronate versus a full 10 years of therapy . Later, however, once-weekly preparation of alendronate (70 mg) has greatly exceeded daily administration based on improved ease of use, and tolerability that is equivalent to or better than daily therapy .
The decision about whether to stop therapy with bisphosphonate after a finite period of time is subject to debate. Further analysis of the FLEX data revealed that women with a femoral neck BMD T score of −2.5 or below at the 5-year mark had a higher risk of subsequent fractures after discontinuation , so some centers have adopted strategies where bisphosphonate treatment is discontinued, only in patients where t-score is > −2,5.
Risedronate is a pyridinyl amino-bisphosphonate that increases bone mass and prevents fractures . In two studies one US  and one multinational  VERT (Vertebral Efficacy with Risedronate Therapy) studies, 1,226 and 2,458 postmenopausal women with at least one prior vertebral fracture were were enrolled and randomized to treatment with 5 mg of risedronate or Ca + D alone. Women receiving risedronate exhibited 41–49% reduction in vertebral fractures and 33–39% reduction in nonvertebral fractures. The drug was also tested In the Hip Intervention Program study, where risedronate 5 mg significantly reduced hip fractures among women with confirmed low bone mass but not among those selected primarily on the basis of fall risks without documented osteoporosis .
Ibrandronate either orally (daily or monthly) or intravenously reduced markers of bone turnover, increased BMD , and reduced fractures of the vertebrae by 52% . In the pivotal fracture study no significant reduction of hip fractures was seen, but post hoc analyses claimed significant reductions in individuals with baseline BMD t-scores at or below −3.0.
Zoledronic acid is administered as a yearly 5 mg intravenous infusion and significantly reduced both vertebral (by 70%) hip (by 41%) and non-vertebral fractures (by 25%) in postmenopausal women with osteoporosis . The drug was also tested in women and men after surgical repair of a hip fracture, and in this population a significant reduction in subsequent clinical fractures along with a reduction in mortality was seen . As with other iv. Bisphosphonates the main side effects include a post-dose response, characterized by fever, myalgia and arthralgia in about 15–20% of patients. These symptoms are seen mainly after administration of the first dose, but rarely with subsequent dosing, and seem to be less pronounced in patients previously treated with oral bisphosphonates. Due to the higher Cmax achieved with iv bisphosphonates the risk of renal impairment is increased over oral adminsitration. However, if a minimum infusion time of 15 min is adhered to. and a baseline creatinine clearance of 35 ml/min is used at cut off for institution of treatment, no increase in renal side effects over placebo are seen .
1.4 Effects of bisphosphonates in osteopenia
The FIT II study studied 8,704 women with low fermoral neck BMD, but no prevalent vertebral fractures, who were randomized to alendronate (5–10 mg) or placebo for a period of 4 years. The primary endpoint was reduction of all clinical fractures (spine, hip, nonvertebral) . 63% of women exhibited t-scores in the osteopenic range (in this study t-scores between −1,6 and −2,5): Alendronate did not significantly reduce clinical fractures in women with baseline t-scores in the osteopenic range, but induced significant reduction (44%) of morphometric vertebral fractures. The NNT to prevent 1 vertebral fracture ranged between 59 and 363 in the lower and higher osteopenic range, respectively . The FOSIT study evaluated the safety and effects on bone mineral density (BMD) of alendronate 10 mg in postmenopausal women with lumbar spine BMD t-score of −2 or more. After 12 months the incidence of nonvertebral fractures was reduced significantly by 47% .
1.4.1 Parathyroid hormone
Continuous excessive secretion of parathyroid hormone (PTH) (e.g. primary hyperparathyroidism) causes bone catabolism, characterized by cortical bone loss in particular . In contrast, exogenously administered intermittent PTH leading to a peak of excess PTH for about 3 h is anabolic due to stimulation of osteoblastic bone formation and increased skeletal remodeling activity. Daily administration of the approved dose of 20 ug of PTH fragment [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34] (teriparatide) increased BMD by an average of 9.7% in human studies [61, 106, 107] and significantly decreased the risk of vertebral (65% risk reduction in those on 20 ug/day) and nonvertebral fractures (35% with 20 ug/day) and increased BMD at all sites investigated, except for the radial shaft . Nonvertebral fragility fractures were reduced by 53%. The initial decrease at this site, coincides with the maximal increase in cortical porosity seen with the drug at 6 months . Teriparatide increases cancellous bone volume, restores trabecular bone architecture and increases cortical thickness. It also leads to periosteal new bone formation and increases cross-sectional area, potentially increasing cortical bone strength . These are specific cortical effects, which are not seen with anti-resorptive drugs, and they may be responsible for the pronounced reduction of non-vertebral fractures by up to 80% in patients treated for more than 18 months in a post hoc analysis of clinical fractures in the pivotal PTH trial .
Full length PTH [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84] has also been tested as a treatment modality for osteoporosis. The dose used was 100 ug/Day, which is equivalent to a PTH [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34] dose of 40 ug. In a study on 2,532 postmenopausal women, PTH[1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84] increased spine and hip BMD by 6,9 and 2,1%, respectively, and reduced the risk for new or worsened vertebral fractures by 40%. No reduction of nonvertebral fractures was demonstrable .
PTH [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34] and PTH [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84] have both been associated with nausea, and headache. PTH [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34] 20 ug/day may lead to asymptomatic mild hypercalcemia, a side effect seen more frequently with PTH [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84], where dose reduction regimens had to be instituted in a significant number of patients in order to avoid symptomatic hypercalcemia . Clinical trials of teriparatide were terminated early by the finding of osteosarcoma in Fisher rats , and similar effects were seen with PTH [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84]. However after widespread use in humans no significant increase in osteosarcoma cases beyond the background rate has been detected. Due to this finding in the initial trial and in repeated toxicology trials in rats, PTH is recommended for treatment for a limited period of 24-months.
There is an enhanced effect on bone mass when PTH is sequentially followed by antiresorptives like alendronate  or estrogen , most probably due to a reduction of the remodeling space brought about by these agents. If some kind of antiresorptive treatment is not given, bone mass will return to baseline within 2 years after discontinuation of PTH, albeit anti-fracture efficacy seems preserved . Oral bisphosphonates started prior to or concurrently with PTH may attenuate bone mass improvement and bone marker increases seen with PTH alone. Iv. Bisphosphonates seem to be causing less blunting of the BMD and marker response .
PTH is currently used most commonly in adults with severe osteoporosis,—many of whom have had fractures while on other antiosteoporotic agents or have had intolerance to bisphosphonates, and will rarely have indications in osteopenic patients.
The discovery of the receptor activator of the nuclear factor kappa B ligand RANKL/RANK/osteoprotegerin (OPG) pathway regulating osteoclastic differentiation has defined new targets for inhibition of osteoclastic bone resorption. Denusomab, a specific recombinant humanized monoclonal antibody against RANKL, is the most effective suppressor of bone resorption yet developed. It reduces bone turnover by over 95% . Consequently the BMD increases seen are more pronounced than with other antiresorptives. In the pivotal FREEDOM (Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months) study of nearly 8,000 women , denosumab reduced the risk of new radiographic vertebral fracture by 68%, with a cumulative incidence of 2.3% in the Denosumab group versus 7.2% in the placebo group. Denosumab significantly reduced the risk of hip and nonvertebral fracture by 40% and 20%, respectively. In clinical trials with Denosumab, overall adverse events were similar to placebo. There was no increase in the risk of cancer, infection, cardiovascular disease, delayed fracture healing, or hypocalcemia. In the osteoporosis trials with Denosumab there were no cases of osteonecrosis of the jaw. In the oncology trials with Denosumab, however, the risk of ONJ was found to be similar to that of Zoledronic acid .
1.4.3 Strontium ranelate
Daily intake of strontium ranelate has been shown to reduce the risk of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis or a prevalent vertebral fracture or both. The exact MOA of strontium ranelate is still poorly defined, however, but the drug increases matrix mineralization and reduce spine fractures by 38% after 3 years [118, 119]. In the pivotal trial on nonvertebral fractures no significant overall reduction of hip fracture was seen, but in a high risk subgroup (women over 74 years old with low BMD at the femoral neck), a significant reduction of 36% was seen . Other post hoc analyses have demonstrated efficacy in women with osteopenia and women older than 80 years .
Amino-bisphosphonates, taken orally or intravenously, remain the dominant treatment modalities for osteoporosis. They reduce fracture risk in osteoporotic as well as osteopenic individuals. Questions exist about the very-long-term safety of these drugs, but the best data available so far , suggest that 10 years with 90% suppression of bone turnover is safe. Denosumab constitutes a future alternative to bisphosphonates. In younger postmenopausal women with osteopenia, estrogen or estrogen/progestin still has a place as a short term (up to 5 years) treatment, especially in women with menopausal symptoms. Similarly SERMs should be considered in younger postmenopausal women, especially those at increased risk of breast cancer. In males with low testosterone levels, testosterone substitution is indicated as it improves skeletal integrity. We still need long term controlled studies on this treatment, but the risk of prostate cancer does not seem to be as big as previously anticipated. Teriparatide, would currently rarely be considered in women or men with cheaper anabolics available, however, initial therapy with anabolics to bring osteopenic patients out of the risk zone followed by an antiresorptive would probably be the ideal treatment.
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.